Australian nutraceutical firm Nutrafruit is fine-tuning its plum-derived formulations as it eyes expansion in East Asia, with continued scientific research lending credibility to its health claims.
Australian bio-pharmaceutical firm MGC Pharmaceuticals is eyeing expansion in East and South East Asia with its cannabis-based nutraceutical products, after having recently launched in China.
Nootropics in New Zealand, cordyceps in South Korea, and the impact of China's daigou clampdown on companies like Swisse owner H&H all feature among our five most read stories on social media this month.
The consumption of elderberry (Sambucus nigra) has strong antiviral potential against influenza infection, especially in the later stages of the virus, researchers in Australia have found.
Australian firm Life-Space Probiotics is ramping up its China activity from multiple angles, with plans in place to grow its presence on the daigou platform, drive NPD, and raise consumer awareness.
Aussie exporter Jatenergy has taken to developing its own brand of functional foods and health supplements, in the hopes of expanding further in China and entering several other APAC markets.
Toddlers who consumer fortified cow's milk have higher dietary nutritional adequacy than those who drink regular cow's milk, according to the findings of a new RCT from New Zealand.
US-based direct-selling health and wellness firm Plexus Worldwide recently launched in Australia, signifying its first step into the Asia-Pacific region.
Australian social influencer-backed health and wellness company Keep It Cleaner is banking on minimalist ingredients and multi-faceted expansion to break into the Asian market.
Pharmako Biotechnologies is aiming to build a 'calendar of studies' that will fully explore the health benefits and variety of applications of its proprietary curcumin ingredient, HydroCurc.
The second phase of New Zealand's High-Value Nutrition National Science Challenge will see a significant portion of its work focused on China, alongside New Zealand and Singapore.
Read about Blackmores' strategy overhaul in the wake of weak Q3 results, Bod Australia's continuing CBD innovations, Sirio Pharma's global R&D plans, and probiotics news from BLIS Technologies and Indian start-up MO's Superfoods.
CBD firm Bod Australia has embarked on a first-of-its-kind clinical trial on medical cannabis for Tourette syndrome patients, while continuing to expand its supplements business in countries with a more conducive regulatory environment than its home market.
Australia supplements giant Blackmores has announced weak Q3 results thanks to slower domestic and China sales, but the firm is confident its new development strategies will get it back on track.
New Zealand probiotics firm BLIS Technologies has its eye on new product development and APAC growth, spurred by its recent financial performance and an additional Australian regulatory approval.
